OPTN - OptiNose, Inc.
| Previous close | 1.1800 |
| Open | 1.1900 |
| Bid | 1.2000 x 2200 |
| Ask | 1.2100 x 1100 |
| Day's range | 1.1800 - 1.2200 |
| 52-week range | 1.0700 - 4.3000 |
| Volume | |
| Avg. volume | 299,555 |
| Market cap | 134.347M |
| Beta (5Y monthly) | -0.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
US$4.17: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results
Shareholders might have noticed that OptiNose, Inc. ( NASDAQ:OPTN ) filed its quarterly result this time last week. The...
- Zacks
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
OptiNose, Inc.'s (NASDAQ:OPTN) Business Is Trailing The Industry But Its Shares Aren't
With a median price-to-sales (or "P/S") ratio of close to 3.1x in the Pharmaceuticals industry in the United States...
- Simply Wall St.
We're Not Very Worried About OptiNose's (NASDAQ:OPTN) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Zacks
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Simply Wall St.
OptiNose, Inc.'s (NASDAQ:OPTN) top owners are private equity firms with 37% stake, while33% is held by institutions
To get a sense of who is truly in control of OptiNose, Inc. ( NASDAQ:OPTN ), it is important to understand the...
- Simply Wall St.
Analysts Are More Bearish On OptiNose, Inc. (NASDAQ:OPTN) Than They Used To Be
The latest analyst coverage could presage a bad day for OptiNose, Inc. ( NASDAQ:OPTN ), with the analysts making...
- Simply Wall St.
OptiNose Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
OptiNose ( NASDAQ:OPTN ) Third Quarter 2022 Results Key Financial Results Revenue: US$20.1m (down 8.0% from 3Q 2021...
- Zacks
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Shareholders in OptiNose (NASDAQ:OPTN) are in the red if they invested five years ago
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
- Simply Wall St.
When Can We Expect A Profit From OptiNose, Inc. (NASDAQ:OPTN)?
We feel now is a pretty good time to analyse OptiNose, Inc.'s ( NASDAQ:OPTN ) business as it appears the company may be...
- Zacks
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
